A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06868277
Trial Phases:	Phase III	Protocol IDs:	D702GC00001 (primary) NCI-2025-06305 2024-517780-24-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT06868277

Summary

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig
compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and
whose tumors express PD-L1.

Objectives

This is a Phase III, two-arm, randomized, double-blind, global, multicenter study
assessing the efficacy and safety of rilvegostomig compared to pembrolizumab as a 1L
treatment for patients with mNSCLC whose tumors express PD-L1.

Treatment Sites in Georgia

Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
144 Bill Carruth Parkway
Suite 3100
Hiram, GA 30141
770-281-5131
www.ngoc.com

Northwest Georgia Oncology Centers - Douglasville
6002 Professional Parkway
Suite 140
Douglasville, GA 30134
770-281-5101
www.ngoc.com

Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
157 Clinic Avenue
Suite 202
Carrollton, GA 30117
770-281-5101
www.ngoc.com

Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
340 Kennestone Hospital Blvd.
Suite 100
Marietta, GA 30060
770-281-5101

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.